Open AccessTherapy for erosive esophagitis induced by mixed reflux in patients with CAD
Author(s) -
О. Н. Минушкин,
А. Г. Шулешова,
K. A. Bondarev,
Д. В. Данилов
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-14-73-77
Subject(s) - pantoprazole , medicine , reflux esophagitis , gastroenterology , esophagitis , reflux , gerd , combination therapy , disease , omeprazole
The article presents the results of using a combination of PPI (pantoprazole) and UDCA for the treatment of erosive esophagitis induced by mixed reflux in patients with coronary artery disease. A total of 62 patients with EGDS-proven erosive esophagitis were enrolled in the study. The patients were divided into two groups: the active treatment group (ATG) which included 34 patients with erosive reflux esophagitis and control group (CG), which included 28 patients with erosive reflux esophagitis without CAD. The patients of both groups received IPP (pantoprazole) 80 mg/day and UDCA at a dosage of 15 mg/kg/day for 12 weeks. (84 days). The study showed that complete epithelialization of esophageal mucosa defects was detected in 100% of ATG patients by Day 84 of therapy, the same was achieved in CG patients by Day 56 of the basic course of therapy. The treatment of EE induced by mixed reflux with a combination of PPI (pantoprazole) at a dose of 80 mg/day and UDCA at a dosage of 15 mg/kg/day was efficient in patients with GERD and CAD as a basic course of therapy for not less than 84 days. An effective dose of UDCA for maintenance therapy is 5 mg/kg/day in combination with PPI at a daily dose of 40 mg for not less than 2 months.